Metformin targets histone acetylation in cancer-prone epithelial cells

Cell Cycle

Volumn 15, Issue 24, 2016, Pages 3355-3361

  Cuyàs, Elisabet ^a,b   Fernández Arroyo, Salvador ^c,d   Joven, Jorge ^c,d   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d The Campus of International Excellence Southern Catalonia ^*  (Spain)

Author keywords

BRCA1; epigenetics; histone acetylation; metformin; mitochondria

Indexed keywords

ACETYL COENZYME A; BRCA1 PROTEIN; CARBON; HISTONE H3; METFORMIN; HISTONE;

AGING; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL NUCLEUS; EPIGENETICS; EPITHELIUM CELL; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HISTONE ACETYLATION; HUMAN; MITOCHONDRION; NOTE; ACETYLATION; BIOLOGICAL MODEL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

ACETYL COENZYME A; ACETYLATION; BRCA1 PROTEIN; CARCINOGENESIS; EPIGENESIS, GENETIC; EPITHELIAL CELLS; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HISTONES; METFORMIN; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 84996835476     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2016.1249547     Document Type: Note

References (65)

1. Pavlov NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism 2016; 23:27-47; PMID:26771115; http://dx.doi.org/10.1016/j.cmet.2015.12.006
2. Wu LE, Gomes AP, Sinclair DA. Geroncogenesis:Metabolic changes during aging as a driver of tumorigenesis. Cancer Cell 2014; 25:12-19; PMID:24434207; http://dx.doi.org/10.1016/j.ccr.2013.12.005
3. Menendez JA, Alarcón T, Joven J. Gerometabolites:The pseudohypoxic aging side of cancer oncometabolites. Cell Cycle 2014; 13:699-709; PMID:24526120; http://dx.doi.org/10.4161/cc.28079
4. Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells:The metabostem crossroads of aging and cancer. Adv Exp Med Biol 2014; 824:117-140; PMID:25038997; http://dx.doi.org/10.1007/978-3-319-07320-0_10
5. Menendez JA. Metabolic control of cancer cell stemness:Lessons from iPS cells. Cell Cycle 2015; 14:3801-11; PMID:25738999; http://dx.doi.org/10.1080/15384101.2015.1022697
6. López-Otín C, Galluzzi L, Freije JM, Madeo F, Kroemer G. Metabolic control of longevity. Cell 2016; 166:802-821; PMID:Can't; http://dx.doi.org/10.1016/j.cell.2016.07.031
7. Yang M, Soga T, Pollard PJ. Oncometabolites:linking altered metabolism with cancer. J Clin Invest 2013; 123:3652-8; PMID:23999438; http://dx.doi.org/10.1172/JCI67228
8. Nowicki S, Gottlieb E. Oncometabolites:tailoring our genes. FEBS J 2015; 282:2796-805; PMID:25864878; http://dx.doi.org/10.1111/febs.13295
9. Morin A, Letouzé E, Gimenez-Roqueplo AP, Favier J. Oncometabolites-driven tumorigenesis:From genetics to targeted therapy. Int J Cancer 2014; 135:2237-48; PMID:25124653; http://dx.doi.org/10.1002/ijc.29080
10. Menendez JA. The metaboloepigenetic dimension of cancer stem cells:Evaluating the market potential for new metabostemness-targeting oncology drugs. Curr Pharm Des 2015; 21:3644-53; PMID:26166605; http://dx.doi.org/10.2174/1381612821666150710150327
11. Corrado M, Scorrano L, Campello S. Changing perspective on oncometabolites:from metabolic signature of cancer to tumorigenic and immunosuppressive agents. Oncotarget 2016; 7:46692-706; PMID:27083002
12. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell Metab 2012; 16:9-17; PMID:22768835; http://dx.doi.org/10.1016/j.cmet.2012.06.001
13. Meier JL. Metabolic mechanisms of epigenetic regulation. ACS Chem Biol 2013; 8:2607-21; PMID:24228614; http://dx.doi.org/10.1021/cb400689r
14. Menendez JA, Alarcón T. Metabostemness:a new cancer hallmark. Front Oncol 2014; 4:262; PMID:25325014; http://dx.doi.org/10.3389/fonc.2014.00262
15. Menendez JA, Corominas-Faja B, Cuyàs E, Alarcón T. Metabostemness:Metaboloepigenetic reprogramming of cancer stem-cell functions. Oncoscience 2014; 1:803-6; PMID:25621295; http://dx.doi.org/10.18632/oncoscience.113
16. Menendez JA, Corominas-Faja B, Cuyàs E, García MG, Fernández-Arroyo S, Fernández AF, Joven J, Fraga MF, Alarcón T. Oncometabolic nuclear reprogramming of cancer stemness. Stem Cell Reports 2016; 6:273-83; PMID:26876667; http://dx.doi.org/10.1016/j.stemcr.2015.12.012
17. Fernández-Arroyo S, Cuyàs E, Bosch-Barrera J, Alarcón T, Joven J, Menendez JA. Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience 2016; 2:958-67.
18. Boukouris AE, Zervopoulos SD, Michelakis ED. Metabolic enzymes moonlighting in the nucleus:Metabolic regulation of gene transcription. Trends Biochem Sci 2016; 41:712-30; PMID:27345518; http://dx.doi.org/10.1016/j.tibs.2016.05.013
19. Su X, Wellen KE, Rabinowitz JD. Metabolic control of methylation and acetylation. Curr Opin Chem Biol 2016; 30:52-60; PMID:26629854; http://dx.doi.org/10.1016/j.cbpa.2015.10.030
20. Dutta A, Abmayr SM, Workman JL. Diverse activities of histone acylations connect metabolism to chromatin function. Mol Cell 2016; 63:547-52; PMID:27540855; http://dx.doi.org/10.1016/j.molcel.2016.06.038
21. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462:739-44; PMID:19935646; http://dx.doi.org/10.1038/nature08617
22. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-67; PMID:21130701; http://dx.doi.org/10.1016/j.ccr.2010.11.015
23. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483:474-8; PMID:22343901; http://dx.doi.org/10.1038/nature10860
24. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI, Jr, Jahromi MS, Xekouki P, et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 2013; 3:648-57; PMID:23550148; http://dx.doi.org/10.1158/2159-8290.CD-13-0092
25. Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23:739-52; http://dx.doi.org/10.1016/j.ccr.2013.04.018
26. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, Liu L, Liu Y, Yang C, Xu Y, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012; 26:1326-38; PMID:22677546; http://dx.doi.org/10.1101/gad.191056.112
27. Salminen A, Kaarniranta K, Hiltunen M, Kauppinen A. Krebs cycle dysfunction shapes epigenetic landscape of chromatin:novel insights into mitochondrial regulation of aging process. Cell Signal 2014; 26:1598-603; PMID:24704120; http://dx.doi.org/10.1016/j.cellsig.2014.03.030
28. Waterfall JJ, Killian JK, Meltzer PS. The role of mutation of metabolism-related genes in genomic hypermethylation. Biochem Biophys Res Commun 2014; 455:16-23; PMID:25111818; http://dx.doi.org/10.1016/j.bbrc.2014.08.003
29. Hoekstra AS, de Graaff MA, Briaire-de Bruijn IH, Ras C, Seifar RM, van Minderhout I, Cornelisse CJ, Hogendoorn PC, Breuning MH, Suijker J, et al. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors. Oncotarget 2015; 6:38777-88; PMID:26472283; http://dx.doi.org/10.18632/oncotarget.3224
30. Cluntun AA, Huang H, Dai L, Liu X, Zhao Y, Locasale JW. The rate of glycolysis quantitatively mediates specific histone acetylation sites. Cancer Metab 2015; 3:10; PMID:26401273; http://dx.doi.org/10.1186/s40170-015-0135-3
31. Mentch SJ, Mehrmohamadi M, Huang L, Liu X, Gupta D, Mattocks D, Gómez Padilla P, Ables G, Bamman MM, Thalacker-Mercer AE, et al. Histone methylation dynamics and gene regulation occur through the sensing of one-carbon metabolism. Cell Metab 2015; 22:861-73; PMID:26411344; http://dx.doi.org/10.1016/j.cmet.2015.08.024
32. Mentch SJ, Locasale JW. One-carbon metabolism and epigenetics:understanding the specificity. Ann N Y Acad Sci 2016; 1363:91-8; PMID:26647078; http://dx.doi.org/10.1111/nyas.12956
33. Menendez JA, Folguera-Blasco N, Cuyàs E, Fernández-Arroyo S, Joven J, Alarcón T. Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome. Oncotarget 2016; 7:11959-71; PMID:26943589
34. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014; 2:12; PMID:25184038; http://dx.doi.org/10.1186/2049-3002-2-12
35. Griss T, Vincent EE, Egnatchik R, Chen J, Ma EH, Faubert B, Viollet B, DeBerardinis RJ, Jones RG. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol 2015; 13:e1002309; PMID:26625127; http://dx.doi.org/10.1371/journal.pbio.1002309
36. Anisimov VN. Metformin for aging and cancer prevention. Aging (AlbanyNY) 2010; 2:760-74; PMID:21084729
37. Menendez JA, Cufí S, Oliveras-Ferraros C, Vellon L, Joven J, Vazquez-Martin A. Gerosuppressant metformin:less is more. Aging (Albany NY) 2011; 3:348-62; PMID:21483040; http://dx.doi.org/10.18632/aging.100316
38. Anisimov VN. Metformin:do we finally have an anti-aging drug? Cell Cycle 2013; 12:3483-9; PMID:24189526; http://dx.doi.org/10.4161/cc.26928
39. Anisimov VN. Metformin for cancer and aging prevention:is it a time to make the long story short? Oncotarget 2015; 6:39398-407; PMID:26583576
40. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab 2016; 23:1060-5; PMID:27304507; http://dx.doi.org/10.1016/j.cmet.2016.05.011
41. De Haes W, Frooninckx L, Van Assche R, Smolders A, Depuydt G, Billen J, Braeckman BP, Schoofs L, Temmerman L. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci U S A 2014; 111:E2501-9; PMID:24889636; http://dx.doi.org/10.1073/pnas.1321776111
42. Cuyàs E, Fernández-Arroyo S, Alarcón T, Lupu R, Joven J, Menendez JA. Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis:Evidence for metformin-based “starvation” strategies in BRCA1 carriers. Oncotarget 2016; http://dx.doi.org/10.18632/oncotarget.9732
43. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A:a central metabolite and second messenger. Cell Metab 2015; 21:805-21; PMID:26039447; http://dx.doi.org/10.1016/j.cmet.2015.05.014
44. Lee JV, Carrer A, Shah S, Snyder NW, Wei S, Venneti S, Worth AJ, Yuan ZF, Lim HW, Liu S, et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 2014; 20:306-19; PMID:24998913; http://dx.doi.org/10.1016/j.cmet.2014.06.004
45. Cai L, Sutter BM, Li B, Tu BP. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of histones at growth genes. Mol Cell 2011; 42:426-37; PMID:21596309; http://dx.doi.org/10.1016/j.molcel.2011.05.004
46. Galdieri L, Vancura A. Acetyl-CoA carboxylase regulates global histone acetylation. J Biol Chem 2012; 287:23865-76; PMID:22580297; http://dx.doi.org/10.1074/jbc.M112.380519
47. Gao X, Lin SH, Ren F, Li JT, Chen JJ, Yao CB, Yang HB, Jiang SX, Yan GQ, Wang D, et al. Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia. Nat Commun 2016; 7:11960; PMID:27357947; http://dx.doi.org/10.1038/ncomms11960
48. Heintzman ND, Hon GC, Hawkins RD, Kheradpour P, Stark A, Harp LF, Ye Z, Lee LK, Stuart RK, Ching CW, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459:108-12; PMID:19295514; http://dx.doi.org/10.1038/nature07829
49. Karczmarski J, Rubel T, Paziewska A, Mikula M, Bujko M, Kober P, Dadlez M, Ostrowski J. Histone H3 lysine 27 acetylation is altered in colon cancer. Clin Proteomics 2014; 11:24; PMID:24994966; http://dx.doi.org/10.1186/1559-0275-11-24
50. Vempati RK, Jayani RS, Notani D, Sengupta A, Galande S, Haldar D. p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals. J Biol Chem 2010; 285:28553-64; PMID:20587414; http://dx.doi.org/10.1074/jbc.M110.149393
51. Tan Y, Xue Y, Song C, Grunstein M. Acetylated histone H3K56 interacts with Oct4 to promote mouse embryonic stem cell pluripotency. Proc Natl Acad Sci U S A 2013; 110:11493-8; PMID:23798425; http://dx.doi.org/10.1073/pnas.1309914110
52. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 2009; 459:113-7; PMID:19270680; http://dx.doi.org/10.1038/nature07861
53. Sadikovic B, Andrews J, Carter D, Robinson J, Rodenhiser DI. Genome-wide H3K9 histone acetylation profiles are altered in benzopyrene-treated MCF7 breast cancer cells. J Biol Chem 2008; 283:4051-60; PMID:18065415; http://dx.doi.org/10.1074/jbc.M707506200
54. Cheung P, Tanner KG, Cheung WL, Sassone-Corsi P, Denu JM, Allis CD. Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 2000; 5:905-15; PMID:10911985; http://dx.doi.org/10.1016/S1097-2765(00)80256-7
55. Eberharter A, Becker PB. Histone acetylation:a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002; 3:224-9; PMID:11882541; http://dx.doi.org/10.1093/embo-reports/kvf053
56. Rossetto D, Avvakumov N, Côté J. Histone phosphorylation:a chromatin modification involved in diverse nuclear events. Epigenetics 2012; 7:1098-108; PMID:22948226; http://dx.doi.org/10.4161/epi.21975
57. Martínez-Reyes I, Diebold LP, Kong H, Schieber M, Huang H, Hensley CT, Mehta MM, Wang T, Santos JH, Woychik R, et al. TCA cycle and mitochondrial membrane potential are necessary for diverse biological functions. Mol Cell 2016; 61:199-209; http://dx.doi.org/10.1016/j.molcel.2015.12.002
58. Sutendra G, Kinnaird A, Dromparis P, Paulin R, Stenson TH, Haromy A, Hashimoto K, Zhang N, Flaim E, Michelakis ED. A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation. Cell 2014; 158:84-97; PMID:24995980; http://dx.doi.org/10.1016/j.cell.2014.04.046
59. Matsuda S, Adachi J, Ihara M, Tanuma N, Shima H, Kakizuka A, Ikura M, Ikura T, Matsuda T. Nuclear pyruvate kinase M2 complex serves as a transcriptional coactivator of arylhydrocarbon receptor. Nucleic Acids Res 2016; 44:636-47; PMID:26405201; http://dx.doi.org/10.1093/nar/gkv967
60. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 2012; 150:685-96; PMID:22901803; http://dx.doi.org/10.1016/j.cell.2012.07.018
61. Silvestri A, Palumbo F, Rasi I, Posca D, Pavlidou T, Paoluzi S, Castagnoli L, Cesareni G. Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions. PLoS One 2015; 10:e0136250; PMID:26291325; http://dx.doi.org/10.1371/journal.pone.0136250
62. Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, Richichi B, Raugei G, Wong N, Tang D, et al. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget 2015; 6:24061-74; PMID:26183399; http://dx.doi.org/10.18632/oncotarget.4448
63. Salani B, Ravera S, Amaro A, Salis A, Passalacqua M, Millo E, Damonte G, Marini C, Pfeffer U, Sambuceti G, et al. IGF1 regulates PKM2 function through Akt phosphorylation. Cell Cycle 2015; 14:1559-67; PMID:25790097; http://dx.doi.org/10.1080/15384101.2015.1026490
64. Shi L, Tu BP. Acetyl-CoA and the regulation of metabolism:mechanisms and consequences. Curr Opin Cell Biol 2015; 33:125-31; PMID:25703630; http://dx.doi.org/10.1016/j.ceb.2015.02.003
65. Quirós PM, Mottis A, Auwerx J. Mitonuclear communication in homeostasis and stress. Nat Rev Mol Cell Biol 2016; 17:213-26; http://dx.doi.org/10.1038/nrm.2016.23